(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 401.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Zenas Biopharma's revenue in 2026 is $1,000,000.On average, 8 Wall Street analysts forecast ZBIO's revenue for 2026 to be $66,480,257, with the lowest ZBIO revenue forecast at $63,873,189, and the highest ZBIO revenue forecast at $68,435,559. On average, 8 Wall Street analysts forecast ZBIO's revenue for 2027 to be $3,587,848,248, with the lowest ZBIO revenue forecast at $1,760,292,935, and the highest ZBIO revenue forecast at $5,611,259,613.
In 2028, ZBIO is forecast to generate $8,430,609,120 in revenue, with the lowest revenue forecast at $1,892,145,445 and the highest revenue forecast at $20,325,361,068.